Sugi Predict

Sugi Predict / Compounds / SCHEMBL799808

SCHEMBL799808

SCHEMBL799808

Cc1ccc(N)c(C(=O)Nc2ccc(Cl)cn2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.63
▸ SMN1; SMN2 Q16637 4/20 0.63
▸ TP53 P04637 1/20 0.63
▸ TSHR P16473 1/20 0.63
▸ NFKB1 P19838 1/20 0.63
▸ NFKB2 Q00653 1/20 0.63
▸ RELA Q04206 1/20 0.63
▸ NPC1 O15118 4/20 0.60
▸ HTT P42858 2/20 0.60
▸ ALOX15 P16050 1/20 0.60
▸ F10 P00742 5/20 0.57
▸ POLB P06746 1/20 0.57
▸ L3MBTL1 Q9Y468 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.53
▸ PTK2 Q05397 1/20 0.52
▸ SORT1 Q99523 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3160357 0.90 POLB (0.67) RAB9ASMN1; SMN2TP53TSHRNFKB1
SCHEMBL1998921 0.89 F10 (0.60) RAB9ASMN1; SMN2TP53TSHRNFKB1
SCHEMBL4865759 0.89 RAB9A (0.58) RAB9ASMN1; SMN2TP53NPC1POLB
SCHEMBL17681356 0.86 RAB9A (0.71) RAB9ASMN1; SMN2TP53TSHRNFKB1
SCHEMBL10063541 0.85 RAB9A (0.54) RAB9ASMN1; SMN2TP53TSHRNFKB1
SCHEMBL4857006 0.85 RAB9A (0.56) RAB9ASMN1; SMN2TP53TSHRNFKB1
SCHEMBL6107228 0.84 RAB9A (0.53) RAB9ASMN1; SMN2TP53TSHRNFKB1
SCHEMBL3157341 0.84 RAB9A (0.61) RAB9ASMN1; SMN2TP53TSHRNFKB1
SCHEMBL14345287 0.84 SORT1 (0.73) RAB9ASMN1; SMN2TP53TSHRNFKB1
SCHEMBL6107185 0.84 RAB9A (0.49) RAB9ASMN1; SMN2TP53TSHRNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2542529-B1 URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA LLC PHARMADIALL (RU) 2019-09-04 — — EP disclosed
WO-2017217895-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING ANTICOAGULANT N-(5-CHLOROPYRIDINE-2-YL)-2-({4-[ETHANIMIDOIL(METHYL)AMINO]BENZOYL}AMINO)-5-METHYLBENZAMIDE "PHARMADIALL" LTD (RU) 2017-12-21 — — WO disclosed
US-20170326119-A1 NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR MILLENNIUM PHARMACEUTICALS, INC. 2017-11-16 — — US disclosed
US-9708265-B2 Urethanes, ureas, amidines and related inhibitors of factor Xa PHARMADIALL LIMITED LIABILITY COMPANY (RU) 2017-07-18 — — US disclosed
US-9555023-B2 Pharmaceutical salts and polymorphs of a factor Xa inhibitor MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-01-31 — — US disclosed
US-20160101089-A1 NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR MILLENNIUM PHARMACEUTICALS, INC. 2016-04-14 — — US disclosed
US-9061019-B2 Pharmaceutical salts and polymorphs of a factor Xa inhibitor MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-06-23 — — US disclosed
US-8946269-B2 Crystalline forms of a factor Xa inhibitor PORTOLA PHARMACEUTICALS, INC. (US) 2015-02-03 — — US disclosed
US-8946219-B2 Combination therapy with a compound acting as a platelet ADP receptor inhibitor PORTOLA PHARMACEUTICALS, INC. (US) 2015-02-03 — — US disclosed
US-20140288028-A1 NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR MILLENNIUM PHARMACEUTICALS, INC. 2014-09-25 — — US disclosed
WO-2003050088-A1 SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY ELI LILLY AND COMPANY (US) 2003-06-19 — — WO disclosed
EP-1307444-A2 SUBSTITUTED HETEROCYCLIC AMIDES ELI LILLY AND COMPANY (US) 2003-05-07 — — EP disclosed
US-6498185-B1 ENZYME FACTOR XA INHIBITORS BERLEX LABORATORIES, INC. 2002-12-24 — — US disclosed
WO-2002064567-A2 SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF FACTOR XA ELI LILLY AND COMPANY (US) 2002-08-22 — — WO disclosed
US-6380221-B1 FOR THERAPY OF DISEASE-STATES CHARACTERIZED BY THROMBOTIC ACTIVITY BERLEX LABORATORIES, INC. 2002-04-30 — — US disclosed
WO-2002010154-A2 SUBSTITUTED HETEROCYCLIC AMIDES ELI LILLY AND COMPANY (US) 2002-02-07 — — WO disclosed
EP-1140903-A1 AROMATIC AMIDES ELI LILLY AND COMPANY (US) 2001-10-10 — — EP disclosed
CN-1282329-A I (ortho)-anthranilamide derivatives as anti-coagulants SCHERING AG (DE) 2001-01-31 — — CN disclosed
US-6140351-A FOR TREATING THROMBOSIS BERLEX LABORATORIES, INC. (US) 2000-10-31 — — US disclosed
WO-2000039118-A1 AROMATIC AMIDES ELI LILLY AND COMPANY (US) 2000-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170326119-A1 NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR F12, F11, TFPI RAB9A 1402/4885SMN1; SMN2 3373/4885TP53 4578/4885
US-20140288028-A1 NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR F12, F11, TFPI RAB9A 1402/4885SMN1; SMN2 3373/4885TP53 4578/4885
US-20160101089-A1 NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR F12, F11, TFPI RAB9A 1402/4885SMN1; SMN2 3373/4885TP53 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.